MARK SILVER: Open Payments
NPI 1639178114 · BROOKINGS, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$163 in 8 payments from 8 companies in 2025. Trend: 2023 $294 · 2024 $294 · 2025 $163
Food & beverage: $147Education: $16
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 1 | $29 |
| Amgen Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Novo Nordisk Inc | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: AREXVY, OTEZLA, YUPELRI, REXULTI, JARDIANCE, LEQVIO, Rybelsus, BREZTRI.
Industry payments across OR — which companies pay providers there.
